Project Grant HT9425261E206
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $560K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded the University of California Irvine a $747,092 Project Grant effective September 1, 2026, through August 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). The project, titled "Immune Checkpoint Inhibition-Related Cognitive Impairments: Mechanisms and Mitigation," supports basic and applied biomedical research investigating cognitive side effects associated with immunotherapy...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded the University of California Irvine a $1.35 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) to investigate immune checkpoint inhibition-related cognitive impairments, with a focus on elucidating mechanisms and developing mitigation strategies. The three-year research initiative, effective September 1, 2026 through August 31, 2029, will be conducted at UCI's Irvine, California...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $1,197,813 Project Grant to the University of California, San Diego on August 15, 2025, under the Military Medical Research and Development program (CFDA 12.420) for mechanism dissection and model development of human PD1 (Programmed Death receptor 1) in melanoma. The three-year award, with a completion date of August 14, 2028, supports basic and applied biomedical research investigating immunotherapeutic mechanisms relevant...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $750,000 Project Grant to the University of California Irvine on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) for the project "A Novel Strategy to Improve the Effectiveness of Radiation Therapy in Breast Cancer." The three-year award period runs through April 30, 2029, and supports investigator-initiated biomedical research addressing medical challenges relevant to Service...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $1,197,884 to the University of California, San Diego (UCSD) under the Military Medical Research and Development program (CFDA 12.420) on August 15, 2025, for a three-year performance period extending through August 14, 2028. This project grant funds mechanism dissection and model development of human PD1 (Programmed Death Receptor 1) in melanoma, supporting basic and applied biomedical research aligned with DHA's...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Regents of the University of California, San Francisco a Project Grant of $865,284 under the Military Medical Research and Development program (CFDA 12.420) on August 15, 2026, with completion scheduled for August 14, 2030. The award funds research focused on "Biochemical and Structural Targeting of the GAQ-Mutant Melanoma Subtype," representing investigator-initiated biomedical research aligned with the...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $235,476 project grant to the University of California, Los Angeles (UCLA) Office of Research Administration on November 1, 2025, to develop new cell-mediated immunotherapeutic strategies for neuroendocrine prostate cancer. The two-year award, which concludes October 31, 2027, is funded under the Military Medical Research and Development program (CFDA 12.420) and will be conducted at UCLA's Los Angeles, California facility....
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $590,625 Project Grant to the University of California, Los Angeles (UCLA) effective September 1, 2025, through August 31, 2028, under the Military Medical Research and Development program (CFDA 12.420). The award supports a pilot study investigating dual immunotherapy targeting programmed cell death protein 1 (PD-1) and CD73 in combination with chemotherapy for patients with pancreatic adenocarcinoma, with particular focus on...
- Federal Grant Award Summary The Defense Health Agency awarded UCLA a $1.7 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) for a three-year project period (July 1, 2026–June 30, 2029). The project focuses on the functional evaluation and optimization of chimeric antigen receptor T (CAR-T) cells targeting prostate cancer through cell-cell interaction profiling using engineered nanovials. This research represents advanced biomedical science aimed at...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded the University of California, Davis a $1.7M Project Grant under the Military Medical Research and Development program (CFDA 12.420) for a three-year research initiative running September 1, 2026, through August 31, 2029. The grant supports a novel therapeutic approach to address chemotherapy-induced peripheral neuropathy (CIPN) in prostate cancer patients by targeting soluble epoxide hydrolase (SEH) as a treatment mechanism....